• Canagliflozin Hemihydrate: Applied Workflows for Glucose Res

  2026-06-13

  Canagliflozin hemihydrate delivers precision and reproducibility for glucose metabolism and diabetes mellitus research. This guide distills hands-on protocols, advanced workflow strategies, and evidence-driven troubleshooting to empower metabolic disorder studies beyond traditional SGLT2 inhibitors.

• Berberine Hydrochloride: Protocols & Innovations for Metabol

  2026-06-12

  Berberine hydrochloride unlocks mechanistic and translational advantages in metabolic, cancer, and cardiovascular disease research. This guide details best-practice workflows, troubleshooting strategies, and actionable protocol parameters that maximize reproducibility and scientific impact.

• Anagliptin (SK-0403): Mechanistic Insights for Vascular Phar

  2026-06-12

  Explore the unique DPP-4 inhibition and vasorelaxant mechanisms of Anagliptin (SK-0403), with a deep dive into its Kv channel and SERCA pump modulation. This article offers advanced, evidence-driven perspectives for diabetes and vascular research.

• 2-Deoxy-D-glucose in Cancer Metabolism: Beyond Glycolysis In

  2026-06-11

  Explore the multifaceted role of 2-Deoxy-D-glucose (2-DG) in cancer metabolism and metabolic stress induction. This article provides advanced insights into glycolysis inhibition and the molecular interplay with cellular senescence, offering a unique perspective for oncology researchers.

• Disulfiram: Dopamine β-Hydroxylase Inhibitor & Cancer Resear

  2026-06-11

  Disulfiram is a clinically established dopamine β-hydroxylase inhibitor and copper-binding agent that induces apoptotic cancer cell death by inhibiting proteasomal chymotrypsin-like activity. Extensive evidence supports its use in breast cancer MDA-MB-231 cell research, with robust in vitro and in vivo efficacy benchmarks. This article details the molecular rationale, workflow integration, and current limitations for translational and mechanistic studies.

• MVC Triggers RhoA/ROCK1/MLC2 Pathway to Disrupt Tight Juncti

  2026-06-10

  This study reveals that the Minute Virus of Canines (MVC) hijacks the RhoA/ROCK1/MLC2 signaling axis via direct VP2-ROCK1 interaction, leading to actomyosin contraction and tight junction disassembly. The findings clarify a novel mechanism of viral entry and suggest new anti-viral intervention points within RhoA-mediated pathways.

• Hepatic Cellular Interactions of PEGylated Iron Oxide Nanopa

  2026-06-10

  This study systematically dissects how PEGylated iron oxide nanoparticles interact with distinct hepatic cell types, revealing that both particle size and PEG chain length dictate organ and cellular biodistribution. The findings challenge traditional assumptions about liver nanoparticle clearance, informing rational nanomedicine design to optimize therapeutic targeting and minimize off-target effects.

• Drug-Sensitized Yeast System Enhances mTOR Inhibitor Discove

  2026-06-09

  A recent study introduces a drug-sensitized yeast screening platform that markedly increases sensitivity for identifying mTOR/TOR inhibitors. By genetically modifying yeast to reduce drug efflux and alter TOR pathway gene function, this system enables cost-effective, rapid detection of candidate compounds, with important implications for aging and metabolic research.

• Targeted SPP1 Inhibition in TAMs Reduces Tumor Burden

  2026-06-09

  This study introduces a novel small molecule-based approach to specifically inhibit SPP1 in tumor-associated macrophages (TAMs), leading to significant tumor size reduction in murine models. The findings provide a foundation for developing targeted therapies that modulate the tumor microenvironment, with implications for oncology research and drug development.

• Berberine Hydrochloride: Mechanistic Leverage in Gut–Bone Ax

  2026-06-08

  Explore how berberine hydrochloride unlocks new frontiers in translational research at the intersection of metabolic regulation and osteoimmunology. This article synthesizes mechanistic insights, workflow parameters, and strategic guidance, positioning APExBIO’s berberine hydrochloride as an enabling tool for advanced studies in the gut-bone axis and beyond.

• Iptacopan (LNP023): Selective Oral Inhibition of Complement

  2026-06-08

  Iptacopan (LNP023) is a potent, orally bioavailable inhibitor of complement factor B, enabling precise blockade of the alternative complement pathway. Clinical and preclinical data demonstrate its efficacy in reducing hemolysis and improving hemoglobin levels in PNH, with high selectivity and minimal off-target effects. APExBIO provides Iptacopan for advanced complement activation research.

• VE-822 ATR Inhibitor: Data-Driven Solutions for Cancer Assay

  2026-06-07

  This article delivers scenario-based, evidence-backed guidance for scientists integrating VE-822 (SKU B1383) in cell viability, proliferation, and cytotoxicity workflows. Using real laboratory challenges and comparative data, we detail how this potent ATR inhibitor provides reproducible, sensitive, and scalable solutions—grounded in its robust performance and APExBIO's reliability. Researchers will find actionable strategies to optimize DNA damage response inhibition and enhance radiosensitization studies.

• Hepatic Interactions of PEGylated Iron Oxide Nanoparticles D

  2026-06-06

  This study provides a detailed dissection of how PEG chain length and particle size govern the hepatic accumulation and cellular uptake of iron oxide nanoparticles. By integrating nuclear imaging and primary liver cell models, the research challenges established assumptions about liver nanoparticle clearance and offers actionable insights for nanomedicine design.

• 2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Inflam

  2026-06-05

  Explore how 2-Deoxy-D-glucose (2-DG) enables targeted glycolysis inhibition for advanced research in cancer and inflammatory disease. This deep dive reveals unique metabolic mechanisms and practical assay insights, expanding beyond standard applications.

• Dissecting Drug Response: Improved In Vitro Evaluation in Ca

  2026-06-05

  Schwartz (2022) challenges the routine use of single-parameter viability assays by rigorously distinguishing between growth inhibition and cell death in cancer drug response evaluation. This work demonstrates that most anti-cancer compounds, including nitrogen mustard alkylating agents like chlorambucil, exert mixed effects on both proliferation and cytotoxicity, underscoring the need for multidimensional in vitro assessment strategies.

14816 records 1/988 page Next 12345 下5页 Last page